Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents
- PMID: 23065664
- DOI: 10.1007/s12325-012-0057-1
Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents
Abstract
Introduction: This in-vitro study compared the toxicity of bimatoprost 0.01% containing benzalkonium chloride (BAK) 0.02% with other commercial BAK-free or BAK-containing prostaglandin analogs.
Methods: Six test solutions were evaluated: travoprost 0.004% with polyquaternium-1 0.001% (PQ), PQ, bimatoprost 0.01% with BAK 0.02%, latanoprost 0.005% with BAK 0.02%, tafluprost 0.0015% preservative free (PF), and BAK 0.02%. Phosphate-buffered saline (PBS) was the live control and 70% methanol was the dead control. Confluent human corneal epithelial cells were incubated with test solutions (diluted 1:5 or 1:10 with PBS) or control solutions for 10 or 25 min, after which cells were fluorescently labeled to distinguish live and dead cells. Data were expressed as a percentage of PBS live-cell fluorescence for automated readouts. Live and dead cells were manually counted for numeric analyses.
Results: For 1:5 and 1:10 dilutions using automated readout, cells exposed to bimatoprost with BAK, latanoprost with BAK, and BAK alone demonstrated significant reductions in the live cell signal compared with PBS, travoprost with PQ, and PQ alone (all P < 0.001). They also demonstrated significantly greater toxicity than tafluprost PF for 1:5 dilutions (all P < 0.001) and 1:10 dilutions (P ≤ 0.02), except for 1:10-diluted bimatoprost with BAK (P = 0.41). For 1:5 dilutions using manual cell count, cells exposed to bimatoprost with BAK demonstrated significant reductions in the percentage of live cells compared with PBS (P = 0.02). For 1:10 dilutions using manual cell count, cells exposed to bimatoprost with BAK, latanoprost with BAK, and BAK alone demonstrated significantly greater toxicity than PBS, travoprost with PQ, PQ alone, and tafluprost PF (all P ≤ 0.03). No significant differences were observed among PBS, travoprost with PQ, and PQ alone under any test conditions (P ≤ 0.63).
Conclusion: This study demonstrated that BAKcontaining solutions, including bimatoprost 0.01% with BAK, were toxic to human corneal epithelial cells, whereas BAK-free solutions showed little to no evidence of toxicity.
Similar articles
-
In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells.J Ocul Pharmacol Ther. 2010 Jun;26(3):259-63. doi: 10.1089/jop.2010.0003. J Ocul Pharmacol Ther. 2010. PMID: 20565312
-
In vitro comparative toxicology of polyquad-preserved and benzalkonium chloride-preserved travoprost/timolol fixed combination and latanoprost/timolol fixed combination.J Ocul Pharmacol Ther. 2011 Jun;27(3):273-80. doi: 10.1089/jop.2010.0111. Epub 2011 Mar 16. J Ocul Pharmacol Ther. 2011. PMID: 21410334
-
Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.Adv Ther. 2010 Nov;27(11):837-45. doi: 10.1007/s12325-010-0070-1. Epub 2010 Oct 7. Adv Ther. 2010. PMID: 20931366
-
Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials.J Glaucoma. 2014 Jan;23(1):e69-75. doi: 10.1097/IJG.0b013e3182a075e6. J Glaucoma. 2014. PMID: 23881267
-
Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs.Surv Ophthalmol. 2002 Aug;47 Suppl 1:S105-15. doi: 10.1016/s0039-6257(02)00327-2. Surv Ophthalmol. 2002. PMID: 12204706 Review.
Cited by
-
Safety data on in situ gelling bimatoprost loaded nanovesicular formulations.Data Brief. 2019 Aug 6;25:104361. doi: 10.1016/j.dib.2019.104361. eCollection 2019 Aug. Data Brief. 2019. PMID: 31485469 Free PMC article.
-
The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis.Drugs R D. 2013 Dec;13(4):243-52. doi: 10.1007/s40268-013-0029-1. Drugs R D. 2013. PMID: 24142473 Free PMC article. Clinical Trial.
-
From Eye Care to Hair Growth: Bimatoprost.Pharmaceuticals (Basel). 2024 Apr 27;17(5):561. doi: 10.3390/ph17050561. Pharmaceuticals (Basel). 2024. PMID: 38794131 Free PMC article. Review.
-
Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy.Front Toxicol. 2023 Jul 21;5:1067942. doi: 10.3389/ftox.2023.1067942. eCollection 2023. Front Toxicol. 2023. PMID: 37547228 Free PMC article. Review.
-
Confocal microscopy of epithelial and langerhans cells of the cornea in patients using travoprost drops containing two different preservatives.Pathol Oncol Res. 2014 Jul;20(3):741-6. doi: 10.1007/s12253-014-9755-0. Epub 2014 Mar 13. Pathol Oncol Res. 2014. PMID: 24623372
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical